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Summary
Cryptococcal meningitis (CM) carries a high risk of mortality with increasing incidences 
| INTRODUC TI ON
Cryptococcus neoformans (C. neoformans s.l.) and Cryptococcus gattii (C. gattii s.l.) species complex are opportunistic pathogens, and cryptococcal meningitis (CM) is the most common cause of fungal meningitis by a considerable high morbidity and mortality. It was estimated the global incidence of CM to be substantial at 223 100 cases annually, resulting in 181 100 annual deaths in 2014.
1 This infection is common in immunosuppressed patients including those with HIV or who have undergone solid organ transplantation. [2] [3] [4] There has been an increase in the incidence of this disease among immunocompetent hosts that are not HIV-infected or not transplant recipients in recent years. [5] [6] [7] Reports have noted that about half of all reported cases of cryptococcosis are in non-HIV-infected and non-transplant patients (between 44% and 55%). [8] [9] [10] [11] Additionally, CM is associated with excessively high disability and mortality rates. 12, 13 Induction therapy is a critical treatment for CM in non-HIV-infected and non-transplant CM patients. 
| PATIENTS AND ME THODS

| Patients and definitions
We performed a retrospective review of all patients diagnosed with non-HIV-and non-transplant-associated CM at the Third Affiliated
Hospital of Sun Yat-sen University between January 2010 and December 2017. The diagnosis was identified according to physical signs and symptoms along with at least one of the following factors: positive India ink stain microscopy of the CSF or a positive CSF culture for Cryptococcus. 21 The patients were confirmed to be HIVnegative based on negative results of serum HIV antibody tests, and medical records were examined to ensure no patient had undergone organ transplantation. These patients were divided into two groups according to treatment regimens they have received. In group I, the patients were treated with a combination of AmB and 5-FC. In group II, the patients were treated with a combination of FCZ and 5-FC.
Exclusion criteria included (a) presence of severe hepatic or renal damage; (b) antifungal therapy administration before admission; (c) prior surgical intervention due to intracranial hypertension; and (d) recurrent CM.
This study was approved by the Ethics Committees of The Third
Affiliated Hospital of Sun Yat-Sen University. The study was in compliance with the Declaration of Helsinki and its later amendments. All study participants provided informed consent. Identifiable data involving the individuals in this study were encrypted.
| Laboratory examination
Enrolled patients underwent lumbar punctures (LP) at least once a week in accordance with treatment guidelines. 14, 22 Then CSF open pressure, CSF white blood cell count and classification, glucose, protein, India ink stain and cultures were recorded. In addition, other conventional blood tests and imaging studies including brain computerised tomography (CT) and/or magnetic resonance imaging (MRI) were also performed during treatment. CSF burden of cryptococcal organisms was evaluated by CSF cryptococcal organisms count through India ink stain. We use canavanine-glycine-bromothy-
CGB medium showed clear colour change for C. gattii s.l. and can be used to differentiate it from C. neoformans s.l. 
| Therapeutic methods
In group I, all patients were treated with amphotericin B deoxycho- 
| Outcome assessments
The primary outcome was treatment response evaluated at the 12th 
| Assessment of adverse events
Data of adverse events were collected and assessed by National
Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0).
| Statistical analysis
Baseline demographic and clinical characteristics are presented as percentages, mean with standard deviations (SD) or medians with range; comparisons were performed using the chi-square or Fisher's exact tests for categorical data, and with Student's t or Mann-Whitney U tests for continuous data. Efficacy of treatment responses was estimated using the Wilcoxon rank sum test based on the five grades over ten weeks between the two study groups. Chi-square tests were used to compare CSF sterilisation within 2, 4 and 12 weeks. Chi-square and
Fisher's exact tests were used to estimate the incidence of adverse events between groups. Statistical analyses were performed using SPSS statistics version 19 (IBM). All analyses were two-sided and Pvalues of < 0.05 were considered statistically significant.
| RE SULTS
| Basic clinical characteristics
A total of 132 patients were excluded because of exclusion criteria including 50 patients present with severe hepatic or renal damage, 
| CSF sterility
CSF sterility results within 12 weeks are detailed in Table 2 , and no significant differences were observed in the incidence of CSF cryp- 
| Treatment response
The primary treatment response outcome was evaluated in the 12th week following initial therapy. No significant difference was observed in the treatment response rate as shown in Table 3 AmB + 5-FC (n = 43) 
| Adverse events
A total of 38 (88.4%) patients cannot tolerate recommended doses of AmB and 5-FC for they needed dose reduction during the treatment attributed to adverse events. Details of all adverse events are provided in Table 4 
| D ISCUSS I ON
We found that the majority of patients with non-HIV-and non-transplant-associated CM do not tolerate the recommended induction therapy doses of AmB or 5-FC. Our findings were in accordance with those of previous studies which depict medication intolerance as a commonly documented problem in China. 15, 17, 18 Although dosages of AmB and 5-FC were adjusted, the incidence of adverse events in this study was still high (90.7%). AmB activity is concentration-dependent, so it is vital to ensure that drug concentrations reach the level of therapeutic effect. 25, 26 As a result of severe toxic side effects, CM patients are unable to endure the recommended dosages of AmB or 5-FC, which may result in a corresponding decrease of fungicidal activity and response to treatment 14, 16 even increase the risk of relapse. 20, [27] [28] [29] FCZ is widely applied in clinical treatment of deep mycosis and high pharmacological efficacy with few adverse reactions. FCZ combined with 5-FC has been recommended to treat HIV-associated CM. 14 However, limited comparative data related to FCZ combined with 5-FC in treating non-HIV-and non-transplant-associated CM exist. Total fungal infection burden is regarded as an important predictor of poor outcomes. In the present study, while the baseline fungal infection burden was higher in the patients treated with FCZ and 5-FC, the total successful response rate, which include complete and partial responses, was higher compared to the AmB and 5-FC treatment, although these differences did not reach significance (34/47, 72.3% versus 30/43, 69.7%; P = 0.820).
Moreover, the incidence of CSF culture sterility at two weeks, in- Our study was limited due in part to its retrospective nature and the fact that the total number of enrolled patients was limited.
Moreover, we did not further apply molecular methods to distinguish C. neoformans s.l. from C. gattii s.l. after CGB culture. As a result, a definite consensus regarding the efficacy of FCZ and 5-FC therapy for non-HIV-and non-transplant-associated CM was needed. Future studies, particularly additional prospective large-scaled randomised controlled trials including molecular methods to distinguish cryptococcal species, are warranted in order to definitively determine the best standard of care in these patient populations.
In conclusion, our study found that the majority of patients with non-HIV-and non-transplant-associated CM do not tolerate the recommended doses of AmB during induction therapy due to side effect severity. Adjusting the dosages and treatment regimen of AmB still resulted in a high incidence of adverse events in this group.
We showed that FCZ and 5-FC combination therapy had relatively high efficacy with few adverse events in treating non-HIV-and nontransplant-associated CM. FCZ and 5-FC combination treatment proved to be a good alternative therapy for patients with non-HIVand non-transplant-associated CM. This treatment regimen is particularly efficacious in patient groups that are unable to tolerate the recommended dosages of AmB or in those that are not suitable candidates for AmB treatment.
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